SKIN AND GUT MICROBIOME ALTERATIONS IN PSORIASIS.DENIPLANT NUTRITIONAL INTERVENTION
Major Gheorghe Giurgiu1, Prof Dr Med Manole Cojocaru2
1Deniplant-Aide Sante Medical Center, Biomedicine, Bucharest, Romania
deniplant@gmail.com; Telephone: +40 744 827 881
https://orcid.org/0000-0002-5449-2712
2Academy Romanian of Scientists
Titu Maiorescu University, Faculty of Medicine, Bucharest, Romania
cojocaru.manole@gmail.com; Telephone: +40 723 326 663
https://orcid.org/0000-0002-7192-7490
Abstract
Background Psoriasis is a chronic inflammatory skin disease. It is also defined as an immune-mediated pathology, with cutaneous and systemic manifestations that has numerous consequences on the quality of life of patients who suffer from it. It is known that also calorie restriction and low calorie diet can improve the symptomatology and the development of psoriasis. It is known that the immune system and the microbiome are linked.
Objectives New evidences suggest that the microbiome may play a pathogenic role in psoriatic disease. The aim of the present project is to investigate whether a dietary intervention could ameliorate the clinical manifestations and modulate the gut microbiota of individuals with psoriasis.
Materials and methods Nutrition plays an important role in the development of psoriasis and it can modulate microbiota and microbiome composition.
Results Among environmental factors, diet plays a central role therefore incorrect nutritional habits and excessive body weight can increase clinical symptoms or even trigger the disease. Such diet-based and nutraceutical approaches to targeting the microbiome may produce a milder side effect profile than current systemic medications. Thus, interventions aimed at the microbiome may be a valuable adjunct for preventing or managing psoriatic disease and its comorbidities.
Conclusion Nutrition plays an important role in the development of psoriasis and its comorbidities. Ultimately, a better understanding of the psoriatic microbiome can lead to the development of new therapeutic modalities that target the shifting microbiota. Thus, interventions aimed at the microbiome may be a valuable adjunct for preventing or managing psoriatic disease and its comorbidities
Keywords: psoriasis, skin and gut microbiome, Deniplant nutritional intervention
The pathogenesis is multifactorial, and the exact driving factor remains unclear. The human microbiome has become an area of utmost interest. The microbiome refers to all the microbes in the human body and their genetic material. The gut-skin axis is the novel concept of the interaction between skin diseases and microbiome through inflammatory mediators, metabolites and the intestinal barrier.
There is much evidence that alterations in the skin and intestinal microbiome play an important role in the pathogenesis of psoriasis, and restoration of the microbiome is a promising preventive and therapeutic strategy for psoriasis (1).
There is a close association between psoriatic attacks and microbiome alterations (dysbiosis), characterized by altered diversity and composition, as well as blooms of opportunistic pathogens (2).
Microbiome perturbations are associated with several immune-mediated dermatoses, such as psoriasis, atopic dermatitis and acne vulgaris. The interactions between the microbiota and the host are mediated mainly through bacterial components and microbial metabolites. The gut microbiota has a regulatory effect on systemic immunity, causing the functioning and dysfunction of distant organ systems (3).
The skin has a particularly complicated connection with the gut, but the underlying mechanism is incompletely understood, and this phenomenon is at least partially attributed to the disruption of the intestinal barrier (4).
Given the gut microbial contribution to inflammatory disease and the immune system, there exists an opportunity to intentionally modulate the microbiome for therapeutic purposes. The shaping of skin and gut microbial composition and function depends largely on environmental factors, particularly diet, rather than human genetics (5). Restoration of the gut microbiome is a promising preventive and therapeutic strategy in a number of clinical conditions (6).
Some probiotics have been shown to ameliorate skin inflammation by modulating immune responses in the host, but there is no evidence of their potential role in treating psoriasis (7).
Microbiome alterations, such as abnormal colonization by C. albicans andS. aureus, may act as potential pathogenic factors for psoriasis (8). The gut-skin axis is the novel concept of the interaction between skin diseases and microbiome through inflammatory mediators, metabolites and the intestinal barrier (9). The regulation and symbiosis (harmony) of the gut bacteria and immune system are important for inhibiting an immune response against the body’s own tissues. The gut dysbiosis in people with psoriasis could lead to more inflammation and activation of immune cells. All of these changes could ultimately affect the level of inflammation in the body (10).
With the help of Deniplant brand, Gheorghe Giurgiu has developed several nutraceuticals for psoriasis that act as immunomodulators of the human microbiome.
Hence, it is crucial to understand nutraceuticals impact on the psoriatic skin microbiota which is thought to be perturbed, our study provides insight into the skin microbiota in psoriasis and how it is modulated by nutraceuticals and diet.
Deniplant tea prevents and treats the internal causes that trigger and maintain psoriasis by naturally modulating the intestinal and skin microbiome. Removing dysbiosis from the intestinal microbiota can prevent and eliminate complications caused by psoriasis.
Deniplant tea contains cultivated medicinal plants, berries and flora, fruit tree buds.
With the understanding that the brain-gut-skin axis exists, it is now clear that intestinal microbes have significant effects on psoriasis.
We confirmed the association of psoriasis and gut microbiota dysbiosis. This study provides a detailed and comprehensive systematic review regarding gut microbiome in patients with psoriasis. These results are supported by clinical observations based on a case series showing improvement in psoriatic skin lesions after modulation of gut microbiota by Deniplant nutraceuticals. Food choices can affect microbiome composition and improve the severity grade of psoriatic disease.
Patient with psoriasis
Before treatment After treatment
Because Deniplant treatment addresses the internal causes that trigger and maintain the disease, without ointments or other medications, its duration depends on how quickly the body resolves dysbiosis of the intestinal microbiome, and can be between 4-6 months.
If the disease is older, the treatment can exceed 12 months.
After all the lesions healed, there were patients who never had psoriasis again, but there were also patients whose disease reappeared after 10-15 years.
Conclusions
The skin and gut microbiome may play a role in the dysregulation of the immune system during psoriasis and psoriatic arthritis. The new therapeutic strategies for psoriasis are supported by clinical observations based on a case series showing improvement in psoriatic skin lesions after antibiotic treatment, modulation of gut microbiota by probiotics or fecal microbial transplantation. Unfortunately, the direct link between the skin microbiota and the pathogenesis of psoriasis remains to be clearly established.
The treatment of psoriasis, similar to other immune-mediated complex diseases, is limited to improving the symptoms, due to the lack of effective therapy. On the basis of these findings, the treatment of skin inflammation by nutraceuticals is favored, since its therapeutic management is simple, safe, and cheap.
References
1 Sikora M, Stec A, Chrabaszcz M. Gut Microbiome in Psoriasis: An Updated Review. Pathogens. 2020; 9(6): 463.
2 Hsu DK, Fung MA, Chen HL. Role of skin and gut microbiota in the pathogenesis of psoriasis, an inflammatory skin disease. Medicine in Microecology. 2020; 4: 100016
3 Shapiro J, Cohen NA, Shalev V, et al. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J. Dermatol. 2019; 46: 595-603.
4 Huang L, Gao R, Yu N, et al. Dysbiosis of gut microbiota was closely associated with psoriasis. Sci. China Life Sci.2019; 62: 807-15.
5 Raut G, Wairkar S.Management of psoriasis with nutraceuticals: An update. Complement Ther Clin Pract. 2018; 31: 25-30.
6 Damiani G, Bragazzi NL, McCormick TS, et al. Gut microbiota and nutrient interactions with skin in psoriasis: A comprehensive review of animal and human studies. World J Clin Cases. 2020; 8(6): 1002-12.
7 Chen L, Li J, Zhu W. Skin and Gut Microbiome in Psoriasis: Gaining insight into the pathophysiology of it and finding novel therapeutic strategies. Front. Microbiol. 2020.
8 Hortelano GH, Yermekbayeva B, Kushugulova A. Psoriasis Is Associated With Elevated Gut IL-1α and Intestinal Microbiome Alterations. Front Immunol. 2020; 11: 571319.
9 Olejniczak-Staruch I, Ciążyńska M, Sobolewska-Sztychny D, et al. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 2021; 22(8): 3998.
10 Huang L, Gao R, Yu N, et al. Dysbiosis of gut microbiota was closely associated with psoriasis. Sci China Life Sci. 2019; 62(6): 807-15.